^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD74-targeted antibody-drug conjugate

    Related drugs:
    2ms
    A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML (clinicaltrials.gov)
    P1/2, N=13, Terminated, Servier Bio-Innovation LLC | N=132 --> 13 | Trial completion date: Aug 2030 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2028 --> Oct 2025; Sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Venclexta (venetoclax)
    9ms
    Preclinical in vitro and in vivo evidence for CD74-targeting as effective treatment strategy for cutaneous T cell lymphomas. (PubMed, Br J Dermatol)
    CD74 is expressed across common CTCL subtypes, and CD74-targeting efficiently kills CTCL cells in vitro and in vivo. Our data thus identify CD74-targeting as highly promising treatment strategy for CTCL.
    Preclinical • Journal
    |
    CD74 (CD74 Molecule)
    |
    gemcitabine • bezetabart debotansine (STRO-001)
    9ms
    A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML (clinicaltrials.gov)
    P1/2, N=132, Recruiting, Servier Bio-Innovation LLC | Initiation date: Nov 2024 --> Feb 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    Venclexta (venetoclax)
    over1year
    A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML (clinicaltrials.gov)
    P1/2, N=132, Not yet recruiting, Servier Bio-Innovation LLC
    New P1/2 trial • Combination therapy
    |
    Venclexta (venetoclax)
    over1year
    Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov)
    P1, N=70, Completed, Sutro Biopharma, Inc. | Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Jan 2023 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    bezetabart debotansine (STRO-001)
    almost2years
    Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=9, Terminated, BioNova Pharmaceuticals (Shanghai) LTD. | N=50 --> 9 | Trial completion date: Dec 2024 --> Dec 2023 | Recruiting --> Terminated; Due to company decision
    Enrollment change • Trial completion date • Trial termination • Metastases
    |
    bezetabart debotansine (STRO-001)
    2years
    Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates. (PubMed, Clin Transl Med)
    In summary, our study opens the door for further evaluation of ADCs in several indications not explored before.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD74 (CD74 Molecule) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule) • CD33 (CD33 Molecule) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • PTK7 (Protein Tyrosine Kinase 7) • TFRC
    |
    Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • Tivdak (tisotumab vedotin-tftv)
    over2years
    Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities (ESMO 2023)
    Conclusions CD74 and SLAMF7 is highly present in melanoma, correlates with PD-L1 expression and predict response to anti-PD-(L)1 therapies. This finding suggests to explore potential combinations between ADCs against these targets and anti-PD-(L)1 therapies.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CD22 (CD22 Molecule) • SLAMF7 (SLAM Family Member 7)
    |
    PD-L1 expression • CD74 expression
    over2years
    Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=50, Recruiting, BioNova Pharmaceuticals (Shanghai) LTD. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CD74 (CD74 Molecule)
    |
    CD74 expression
    |
    bezetabart debotansine (STRO-001)
    almost3years
    Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001. (PubMed, Oncotarget)
    In MCL Mino and Jeko-1 xenografts, STRO-001 starting at 3 mg/kg significantly prolonged survival or induced tumor regression, respectively, leading to tumor eradication in both models. In summary, high CD74 expression levels in tumors, nanomolar cellular potency, and significant anti-tumor in DLBCL and MCL xenograft models support the ongoing clinical study of STRO-001 in patients with B-cell NHL.
    Journal
    |
    CD74 (CD74 Molecule)
    |
    CD74 expression
    |
    bezetabart debotansine (STRO-001)
    3years
    Pediatric Acute Myeloid Leukemia with Co-Occurring BCR::ABL and CBFA2T3::GLIS2 Dual Fusion with Deep Response to FOLR1-Targeting Antibody Drug Conjugate Stro-002 and Tyrosine Kinase Inhibitor (ASH 2022)
    Review of diagnostic genomic profile mid induction showed a BCR::ABL minor breakpoint fusion as well as CBF::GLIS fusion.The child began AML induction on COG AAML1831 trial randomized to the experimental arm with CPX-351 and gemtuzumab ozogamicin (GO). Due to lack of response to AML therapy at end of Induction (EOI) I, she was taken off protocol and started on modified ALL regimen for Induction II consisting of cytarabine, low dose weekly methotrexate and bimonthly peg-asparaginase with addition of an oral TKI, dasatinib...Given availability of FOLR1 directed ADC on single-patient compassionate use basis, patient received single agent STRO-001 on a bi-monthly basis...Long-term follow-up is required to assess durability of remission. Additional testing of this approach in a larger patient population is needed to determine the role of STRO-002 in this high-risk pediatric AML population.
    Clinical • IO biomarker
    |
    FOLR1 ( Folate receptor alpha ) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2)
    |
    FOLR1 expression • CD8 negative
    |
    dasatinib • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • luveltamab tazevibulin (STRO-002) • bezetabart debotansine (STRO-001)